06.16.14
OrbusNeich has launched the Sapphire II NC coronary dilatation catheter, a non-compliant balloon catheter engineered to cross tight lesions.
Sapphire II NC's proprietary balloon processing results in an excellent profile for primary and repeated lesion entry, according to the Hong Kong, China-based company. Its enhanced distal Z-Tip with advanced laser welding technology results in “zero” transition between the distalleading tip and conventional steerable guidewires. Sapphire II NC is available in a broad range of sizes, from 1.75 mm to 5 mm, with a catheter working length of 140 cm.
"This exciting launch reflects our ongoing commitment to the development of innovative tools for interventional cardiologists,” said B. Wayne Johnson, president and chief operating officer of OrbusNeich. “Sapphire II NC is the latest addition to the OrbusNeich product portfolio following availability of the COMBO Dual Therapy Stent last year.”
Toshiya Muramatsu, M.D.,of the Saiseikai Yokohama-City Eastern Hospital in Japan, said, “Sapphire II NC with its reduced and improved profile performs well not just as a post but also as a pre dilatation balloon. Robustness and good crossability are very desirable features for a non-compliant balloon."
OrbusNeich designs, develops, manufactures and markets vascular disease treatment devices. Its products include a pro-healing stent (Genous Stent) and the COMBO Dual Therapy Stent, which is designed to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of pro-healing technology and an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents, the company said. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich also sells stents under the brand names of Azule, R stent, Scoreflex, Sapphire, Sapphire II and Sapphire NC. The company has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries.
Sapphire II NC's proprietary balloon processing results in an excellent profile for primary and repeated lesion entry, according to the Hong Kong, China-based company. Its enhanced distal Z-Tip with advanced laser welding technology results in “zero” transition between the distalleading tip and conventional steerable guidewires. Sapphire II NC is available in a broad range of sizes, from 1.75 mm to 5 mm, with a catheter working length of 140 cm.
"This exciting launch reflects our ongoing commitment to the development of innovative tools for interventional cardiologists,” said B. Wayne Johnson, president and chief operating officer of OrbusNeich. “Sapphire II NC is the latest addition to the OrbusNeich product portfolio following availability of the COMBO Dual Therapy Stent last year.”
Toshiya Muramatsu, M.D.,of the Saiseikai Yokohama-City Eastern Hospital in Japan, said, “Sapphire II NC with its reduced and improved profile performs well not just as a post but also as a pre dilatation balloon. Robustness and good crossability are very desirable features for a non-compliant balloon."
OrbusNeich designs, develops, manufactures and markets vascular disease treatment devices. Its products include a pro-healing stent (Genous Stent) and the COMBO Dual Therapy Stent, which is designed to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of pro-healing technology and an abluminal sirolimus drug elution delivered from a biodegradable polymer that achieves full and complete dissipation by 90 days. OrbusNeich's patented endothelial progenitor cell (EPC) capture technology promotes the accelerated natural healing of the vessel wall after the implantation of blood-contact devices such as stents, the company said. The technology consists of an antibody surface coating that captures EPCs circulating in the blood to the device to form an endothelial layer that provides protection against thrombosis and modulates restenosis.
OrbusNeich also sells stents under the brand names of Azule, R stent, Scoreflex, Sapphire, Sapphire II and Sapphire NC. The company has operations in Shenzhen, China; Fort Lauderdale, Fla.; Hoevelaken, The Netherlands; and Tokyo, Japan. OrbusNeich supplies medical devices to interventional cardiologists in more than 60 countries.